Sign In
Buy ALEC
$1.51
-0.110 (-6.79%)
At Close: Jul 31, 2026
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
06:50pm, Wednesday, 06'th Nov 2024
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th Nov 2024
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
05:28pm, Wednesday, 23'rd Oct 2024
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
Alector to Participate in Upcoming Healthcare Conferences
07:00am, Thursday, 29'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will p
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
11:53pm, Thursday, 08'th Aug 2024
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosen
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
07:15pm, Wednesday, 07'th Aug 2024
Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 07'th Aug 2024
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024
Alector to Host Mid-Year Earnings Conference Call
04:05pm, Wednesday, 31'st Jul 2024
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baselin
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
07:00am, Tuesday, 23'rd Jul 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain bar
Alector to Participate in Upcoming Healthcare Conferences
07:00am, Thursday, 09'th May 2024
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will pa
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
07:26pm, Wednesday, 08'th May 2024
Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
11:05am, Thursday, 25'th Apr 2024
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector to Participate in Upcoming Healthcare Conferences
07:00am, Wednesday, 28'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will p
